In this manner, miR-29b by direct targeting DNMT3B operates as an inhibitory factor for tumor growth in cholangiocarcinoma by alleviating the repressive influence of DNMT3B on CDKN2B expression [80]. This evidence concerns the gene DNMT3B and neoplasm.